Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
